Results 141 to 150 of about 1,815 (184)

Gender Bias in Clinical Trials of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. [PDF]

J Diabetes Res
Lora-Escobar SJ, Rodríguez-de Francisco L, López-Feijoo M, Santos-Ramos B, Bellido V, Casado-Mejía R, Acosta-García H.   +6 more
europepmc   +1 more source

Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes. [PDF]

Saudi Med J
Wang G, Wang G.
europepmc   +1 more source

Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort. [PDF]

Medicine (Baltimore)
Higashikawa T, Ito T, Mizuno T, Ishigami K, Kuroki K, Haraguchi T, Yamada S, Sangen R, Kiyosawa J, Saito A, Iguchi M, Nakahashi T, Kasamaki Y, Fukuda A, Kanda T, Okuro M.   +15 more
europepmc   +1 more source

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Ahmed AE, Alhufayyan NS, Qadri HF, Atiah AF, Alhazmi WM, Alhazemi NT, Zalah HA, Nasser FM, Monajid RM, Aljuhani MG.   +9 more
europepmc   +1 more source

Effects of Switching From Another Sodium-Glucose Cotransporter 2 Inhibitor to Tofogliflozin on Nocturia in Patients With Type 2 Diabetes. [PDF]

Cureus
Inoue S, Yasuda H, Yoshida K, Mori K, Ogawa K, Yokotsuka Y, Okamoto H.   +6 more
europepmc   +1 more source

Use of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors in Pulmonary Hypertension. [PDF]

Circ Heart Fail
Aguado B, Ruffenach G, Lacoste-Palasset T, Görlach A, Riou M, Gourmelon M, Bauer F, Humbert M, Schini-Kerth V, Vachiéry JL, Montani D, Antigny F.   +11 more
europepmc   +1 more source

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?

Archives of Medical Science – Atherosclerotic Diseases, 2018
openaire   +2 more sources

Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrence Post-Catheter Ablation Among Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. [PDF]

J Cardiovasc Electrophysiol
Abdelhadi NA, Ragab KM, Elkholy M, Koneru J, Ellenbogen KA, Pillai A.   +5 more
europepmc   +1 more source

An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients [PDF]

Xueting Hu, Xueying Liu, Yaowen Wang, Zengqi Wang   +3 more
core   +2 more sources

Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies. [PDF]

J Obes Metab Syndr
Goto H, Takamura T.
europepmc   +1 more source